Xin Lu

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Transcription Factor

Ejection Fraction

Top Venues

Molecular cancer research : MCR

This page only lists publications with an associated author ORCID identifier.

Publications

Joshua P Plotnik, Zheng Zha, Weiguo Feng, Irene I Lee, Jacob Riehm, Ryan A McClure, Stephanie Sandoval, Tamar Uziel, Erin Murphy, Xin Lu, Lloyd T Lam
MYC Family Amplification Dictates Sensitivity to BET Bromodomain Protein Inhibitor Mivebresib (ABBV075) in Small-Cell Lung Cancer. Molecular cancer research : MCR 22 (8) (2024)
Joshua P Plotnik, Zheng Zha, Weiguo Feng, Irene I Lee, Jacob Riehm, Ryan A McClure, Stephanie Sandoval, Tamar Uziel, Erin Murphy, Xin Lu, Lloyd T Lam
MYC family amplification dictates sensitivity to BET bromodomain protein inhibitor Mivebresib (ABBV-075) in small-cell lung cancer. Molecular cancer research : MCR (2024)
Joshua P Plotnik, Zheng Zha, Weiguo Feng, Irene I Lee, Jacob Riehm, Ryan A McClure, Stephanie Sandoval, Tamar Uziel, Erin Murphy, Xin Lu, Lloyd T Lam
MYC Family Amplification Dictates Sensitivity to BET Bromodomain Protein Inhibitor Mivebresib (ABBV075) in Small-Cell Lung Cancer. Molecular cancer research : MCR 22 (8) (2024)
Joshua P Plotnik, Zheng Zha, Weiguo Feng, Irene I Lee, Jacob Riehm, Ryan A McClure, Stephanie Sandoval, Tamar Uziel, Erin Murphy, Xin Lu, Lloyd T Lam
MYC Family Amplification Dictates Sensitivity to BET Bromodomain Protein Inhibitor Mivebresib (ABBV075) in Small-Cell Lung Cancer. Molecular cancer research : MCR 22 (8) (2024)
Joshua P Plotnik, Zheng Zha, Weiguo Feng, Irene I Lee, Jacob Riehm, Ryan A McClure, Stephanie Sandoval, Tamar Uziel, Erin Murphy, Xin Lu, Lloyd T Lam
MYC Family Amplification Dictates Sensitivity to BET Bromodomain Protein Inhibitor Mivebresib (ABBV075) in Small-Cell Lung Cancer. Molecular cancer research : MCR 22 (8) (2024)